title: Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.
abstract: Recombinant envelope glycoproteins prepared from a subtype B (MN) strain and a subtype E (CM244) strain of HIV-1 were combined to create a bivalent vaccine (B/E) effective against viruses circulating in the United States and Asia. Combining the two antigens resulted in formulations that increased the breadth and potency of the inter-subtype neutralizing response. Antibodies to the bivalent vaccine formulation neutralized viruses possessing diverse phenotypes, including syncytia-inducing and non-syncytia-inducing primary isolates, viruses using either the CCR5 or the CXCR4 chemokine receptors, and viruses differing in their sensitivity to soluble CD4. These studies demonstrate for the first time that the magnitude and quality of the immune response to HIV-1 can be improved by combining recombinant envelope glycoproteins from different genetic subtypes.
authors.affiliation: Genentech, Inc., South San Francisco, California, 94080, USA. pwb@vaxgen.com
authors.forename: P W
authors.initials: PW
authors.lastname: Berman
authors.forename: W
authors.initials: W
authors.lastname: Huang
authors.forename: L
authors.initials: L
authors.lastname: Riddle
authors.forename: A M
authors.initials: AM
authors.lastname: Gray
authors.forename: T
authors.initials: T
authors.lastname: Wrin
authors.forename: J
authors.initials: J
authors.lastname: Vennari
authors.forename: A
authors.initials: A
authors.lastname: Johnson
authors.forename: M
authors.initials: M
authors.lastname: Klaussen
authors.forename: H
authors.initials: H
authors.lastname: Prashad
authors.forename: C
authors.initials: C
authors.lastname: Köhne
authors.forename: C
authors.initials: C
authors.lastname: deWit
authors.forename: T J
authors.initials: TJ
authors.lastname: Gregory
mesh_terms: D016915:AIDS Vaccines; D000818:Animals; D015686:Gene Products, env / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis; D015488:HIV Antigens / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015658:HIV Infections / Q000517:prevention & control / Q000821:virology; D015497:HIV-1 / Q000145:classification* / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D008264:Macrophages / Q000821:virology; D009500:Neutralization Tests; D010641:Phenotype; D011817:Rabbits; D019713:Receptors, CCR5; D019718:Receptors, CXCR4 / Q000378:metabolism; D011994:Recombinant Proteins / Q000276:immunology; D013785:Thailand; D014481:United States
chemical_list: D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; D011994:Recombinant Proteins